Shiyao Group's GLP-1/GIP receptor dual directional agonist peptide injection (SYH2069 injection) has been approved for clinical use in the United States
On December 5, 2025, Shiyao Group (1093. HK) announced that its GLP-1/GIP injectionreceptor dual agonist peptide injection (SYH2069 injection) (hereinafter referred to as the product) has been approved by the US Food and Drug Administration (FDA) for clinical trials in the United States.
This product is expected to become the first GLP-1/GIP receptor dual directional agonist in China to enter the clinical stage. It can selectively activate the cAMP pathway, significantly reduce β - arrestin recruitment, thereby reducing receptor endocytosis and desensitization, and improving drug efficacy and efficacy sustainability. At the same time, combined with the long half-life modification platform technology, this product can achieve deeper and more lasting weight loss effects. In studies on diet induced obesity (DIO) mice and non-human primates, the product showed significantly better effects in weight loss and metabolic improvement compared to similar marketed products. Repeated toxicity studies on non-human primates have shown that the product has good tolerance and no vomiting or gastrointestinal adverse reactions have been observed. This product has excellent efficacy and good safety, and is expected to become a new generation therapy for overweight/obesity and other metabolic diseases.
Li Lai Mu Fengda ® For the first time, Tilpotide has been included in the national medical insurance
On December 7, 2025, the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog" for 2025 was announced, and Eli Lilly GIP/GLP-1RA Mu Fengda ® (Tilpotide Injection) was successfully included. The medical insurance coverage of tilpoltide is applicable to the blood sugar control of adult type 2 diabetes patients: on the basis of diet control and exercise, adult type 2 diabetes patients who still have poor blood sugar control after receiving metformin and/or sulfonylurea drugs. The new version of the directory will be officially implemented from January 1, 2026.
In 2025, the national medical insurance drug catalog successfully added 114 new drugs, including 50 innovative drugs, with an overall success rate of 88%, a significant increase from 76% in 2024. 19 drugs have been included in the first edition of the commercial insurance innovative drug catalog.
Jiaofengda ® (Tilpoltide) is the world's first GIP/GLP-1 dual receptor agonist developed by Eli Lilly. It was included in the national medical insurance list for the first time in 2025. It is applicable to the blood sugar control of adult type 2 diabetes and the weight management of obese or overweight people with complications. It plays a role in regulating insulin and glucagon secretion, delaying gastric emptying, and inhibiting appetite through glucose dependence. It can not only achieve strong glucose reduction (the reduction of glycosylated kaempferon in East Asian people reached 2.1%) and significant weight loss (the average weight loss was 20.9% after 72 weeks of maximum dose treatment), but also have additional benefits of cardiorenal protection and relieving obstructive sleep apnea. The convenient drug delivery method of weekly subcutaneous injection has improved patients Compliance.